Special Issue "JAK-STAT Signalling Pathway in Cancer"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 September 2019

Special Issue Editors

Guest Editor
Dr. Andrew J. Brooks

Diamantina Institute, The University of Queensland, Level 5, Translational Research Institute 37 Kent Street, Woolloongabba, QLD 4102, Australia
Website | E-Mail
Interests: Cytokine Receptors Kinases; JAK2; STAT5; STAT3
Guest Editor
Dr. Tracy Putoczki

The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, VIC 3052, Australia
Website | E-Mail
Interests: Inflammation-associated cancers; How signal transduction by cytokines can modulate tissue homeostasis, and to understand how deregulation of these signalling pathways can promote numerous diseases, including cancer

Special Issue Information

Dear Colleagues,

The JAK-STAT signalling pathway is a major contributor to haematological malignancies, however this signalling pathway is also known to play key roles in promoting solid tumour growth and metastasis. In addition, JAK-STAT signalling has been shown to contribute to a pro-tumorigenic microenvironment through induction of inflammatory responses. JAK-STAT signalling is normally activated by cytokine binding to cytokine receptors as well as some G protein-coupled receptors (GPCRs). Constitutive STAT signalling in cancer can commonly occur due to activating mutations in cytokine receptors or JAKs, while activating mutations in STATs are rare. Mutations that result in increased sensitivity to cytokine activation or extended length of JAK-STAT signalling can also contribute to cancer. Understanding the mechanisms that drive JAK-STAT signalling will be fundamental to our understanding of cancer, the development of novel therapeutic approaches, and ultimately to improved patient outcomes.

Dr. Andrew J. Brooks
Dr. Tracy Putoczki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Cancer
  • Cytokine
  • Cytokine receptor
  • Inflammation
  • JAK
  • STAT
  • Suppressor Of Cytokine Signalling (SOCS)

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top